CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL
NCT00576225
Withdrawn
This study is designed to test whether CT-2103/carboplatin provides improved overall survival compared to paclitaxel/carboplatin in women with NSCLC who have estradiol levels \>30 pg/ml.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/14/2020
Locations: Henry Ford Health System, Josephine Ford Cancer Center, Detroit, Michigan +1 locations
Conditions: NSCLC
Register for Updates
Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
NCT00054210
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of chemotherapy is more effective in treating stage IIIB, stage IV, or recurrent non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of polyglutamate paclitaxel plus carboplatin to that of paclitaxel plus carboplatin in treating patients who have s... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/02/2020
Locations: Not set, Grand Rapids, Michigan
Conditions: Lung Cancer
Register for Updates
Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00551733
Terminated
RATIONALE: Drugs used in chemotherapy, such as carboplatin, paclitaxel, and paclitaxel poliglumex, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving carboplatin together with paclitaxel poliglumex is more effective than giving carboplatin together with paclitaxel in treating non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying carboplatin and paclitaxel poliglume... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
10/02/2020
Locations: West Michigan Regional Cancer and Blood Center, Free Soil, Michigan +1 locations
Conditions: Lung Cancer
Register for Updates
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
NCT02476955
Terminated
An Open-label Phase 1b Study of ARQ 092 in Combination with other Antineoplastic Agents in Subjects with Selected Solid Tumors
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/28/2020
Locations: Not set, Grand Rapids, Michigan
Conditions: Solid Tumors, Ovarian Cancer, Endometrial Cancer
Register for Updates
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
NCT00625898
Terminated
The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/09/2020
Locations: Bixby Medical Center, Adrian, Michigan +44 locations
Conditions: Breast Cancer
Register for Updates
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy
NCT01859741
Terminated
The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 (tarextumab) in combination with etoposide (EP) for 6 cycles followed a Phase 2, multi center, randomized, placebo-controlled portion comparing the efficacy and safety of OMP-59R5 in combination with EP for 6 cycles followed by single agent OMP-59R5 relative to EP alone for 6 cycles in subjects receiving first-line therapy for extensive stage small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
09/07/2020
Locations: University of Michigan Medical Center, Clinical Trials Office, Ann Arbor, Michigan +1 locations
Conditions: Stage IV Small Cell Lung Cancer
Register for Updates
A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer
NCT02259582
Completed
A randomized, double-blind, 3-arm (1:1:1) study in subjects with first-line Stage IV non-squamous NSCLC. The purpose is to test the efficacy and safety of demcizumab, when given in combination with carboplatin and pemetrexed compared to placebo. The administration of carboplatin and pemetrexed is a standard treatment for patients with non-squamous non-small cell lung cancer.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
09/07/2020
Locations: Henry Ford Health System, Detroit, Michigan +1 locations
Conditions: Nonsquamous Nonsmall Cell Neoplasm of Lung
Register for Updates
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
NCT02027428
Completed
Maintenance treatment of advanced stage squamous cell NSCLC. Phase III, randomized, open-label, multi-center study of nab-paclitaxel with best supportive care (BSC) or BSC alone as maintenance treatment after response or stable disease (SD) with nab-paclitaxel plus carboplatin as induction in subjects with stage IIIB/IV squamous cell NSCLC. Subjects who discontinued treatment from the maintenance part for any reason other than withdrawal of consent, lost to follow-up, or death, were entered in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2020
Locations: Detroit Clinical Research Center, Farmington Hills, Michigan +1 locations
Conditions: Squamous Cell Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
NCT02784795
Completed
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2020
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Solid Tumor, Breast Cancer, Colon Cancer, Cholangiocarcinoma, Soft Tissue Sarcoma
Register for Updates
A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
NCT01218516
Completed
The primary objective of this study is to compare the effect of farletuzumab versus placebo in combination with either a platinum agent (carboplatin) with paclitaxel or a platinum agent (carboplatin or cisplatin) with pemetrexed followed by farletuzumab or placebo on investigator-assessed progression free survival (PFS) as determined by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 or definitive clinical disease progression (eg, new occurrence of positive fluid cytology) in chemoth... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2020
Locations: Detroit Clinical Research Center, Farmington Hills, Michigan
Conditions: Adenocarcinoma of the Lung
Register for Updates
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
NCT01450761
Completed
The purpose of the study is to determine whether the addition of Ipilimumab to Etoposide and Platinum therapy will extend the lives of patients with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) more than Etoposide and Platinum therapy alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/06/2020
Locations: St Joseph Mercy Hospital, Ypsilanti, Michigan
Conditions: Small Cell Lung Carcinoma
Register for Updates
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin
NCT01285609
Completed
The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the lives of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2020
Locations: St Joseph Mercy Hospital, Ypsilanti, Michigan
Conditions: Lung Cancer - Non Small Cell Squamous
Register for Updates